{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:07:01Z","timestamp":1792620421307,"version":"4.5.0"},"reference-count":44,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Introduction: The pathogenesis and outcome of cytomegalovirus (CMV) infection after solid organ transplantation (SOT) reflects the interplay between viral replication and CMV-specific immunity. Despite advances in its diagnosis and treatment, CMV continues to cause significant morbidity after SOT. Since CMV is an opportunistic pathogen that occurs as a result of impaired pathogen-specific immunity, laboratory assays that measure CMV-specific immune responses may be useful in assisting clinicians in its management. Methods and Results: The author summarizes the evolving and emerging data on the clinical utility of assays that quantify cell-mediated immune responses to CMV in SOT recipients. The majority of publications are observational studies that demonstrate that a lack or deficiency in CMV-specific cell-mediated immunity is correlated with a heightened risk of primary, reactivation, or recurrent CMV after transplantation. A few prospective interventional studies have utilized CMV-specific cell-mediated immune assays in guiding the duration of antiviral prophylaxis among CMV-seropositive SOT recipients. Likewise, CMV-specific cell-mediated immunity assays have been suggested to inform the need for secondary antiviral prophylaxis and immunologic optimization to prevent CMV relapse after treatment. Conclusions: CMV-specific cell-mediated immune assays are emerging to assist transplant clinicians in predicting a patient\u2019s risk of CMV after transplantation, and these assays have been utilized to individualize the approach to CMV prevention and treatment. The author suggests the conduct of more interventional studies to further solidify the role of CMV-specific cell-mediated immune assays in routine clinical practice.<\/jats:p>","DOI":"10.3390\/v16111781","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T05:33:04Z","timestamp":1731648784000},"page":"1781","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cytomegalovirus Infection After Solid Organ Transplantation: How I Use Cell-Mediated Immune Assays for Management"],"prefix":"10.3390","volume":"16","author":[{"given":"Raymund R.","family":"Razonable","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and the William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: The national health and nutrition examination surveys, 1988\u20132004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nri.2016.38","article-title":"T cell responses to cytomegalovirus","volume":"16","author":"Klenerman","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fcimb.2020.00130","article-title":"Cytomegalovirus Latency and Reactivation: An Intricate Interplay with the Host Immune Response","volume":"10","author":"Forte","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/ajt.15793","article-title":"Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-gamma release assay in kidney transplant recipients treated with antithymocyte globulin","volume":"20","author":"Parra","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2009.02861.x","article-title":"Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients","volume":"10","author":"Eid","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ctr.12686","article-title":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis","volume":"30","author":"Beam","year":"2016","journal-title":"Clin. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-3062.2007.00241.x","article-title":"Clinical features and outcomes of cytomegalovirus retinitis after transplantation","volume":"10","author":"Eid","year":"2008","journal-title":"Transpl. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/ajt.17147","article-title":"A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients","volume":"22","author":"Azar","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e15143","DOI":"10.1111\/ctr.15143","article-title":"Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse","volume":"37","author":"Dioverti","year":"2023","journal-title":"Clin. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tri.13110","article-title":"Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: A multicenter, longitudinal, prospective, observational study","volume":"31","author":"Banas","year":"2018","journal-title":"Transpl. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Descourouez, J.L., Smith, J.A., Saddler, C.M., Mandelbrot, D.A., Odorico, J.S., and Jorgenson, M.R. (2023). Real-World Experience with CMV inSIGHT T Cell Immunity Testing in High-Risk Kidney and Pancreas Transplant Recipients. Ann. Pharmacother., 10600280231207899.","DOI":"10.1177\/10600280231207899"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rogers, R., Saharia, K., Chandorkar, A., Weiss, Z.F., Vieira, K., Koo, S., and Farmakiotis, D. (2020). Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4848-8"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/TP.0000000000002396","article-title":"Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients","volume":"103","author":"Meesing","year":"2019","journal-title":"Transplantation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1432-2277.2009.01017.x","article-title":"A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection","volume":"23","author":"Eid","year":"2010","journal-title":"Transpl. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantisan","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e14011","DOI":"10.1111\/tid.14011","article-title":"Role of cytomegalovirus specific cell-mediated immunity in the monitoring of cytomegalovirus infection among living donor liver transplantation adult recipients: A single-center experience","volume":"25","author":"Bhugra","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","article-title":"Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial","volume":"71","author":"Jarque","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","first-page":"e10","article-title":"Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: Predictive value of the immediate post-transplant assessment","volume":"25","author":"Vinuesa","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jinf.2017.05.020","article-title":"CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy","volume":"75","author":"Gentil","year":"2017","journal-title":"J. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1086\/654931","article-title":"Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients","volume":"202","author":"Abate","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jiaa503","article-title":"Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation","volume":"223","author":"Facundo","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chanouzas, D., Small, A., Borrows, R., and Ball, S. (2018). Assessment of the T-SPOT.CMV interferon-gamma release assay in renal transplant recipients: A single center cohort study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193968"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/tid.12417","article-title":"Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+\/R\u2212 solid organ transplant recipients","volume":"17","author":"Navarro","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of Preemptive Therapy vs. Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective Assessment of Cytomegalovirus Immunity in High-Risk DonoR\u2212Seropositive\/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","article-title":"CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+\/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy","volume":"102","author":"Jarque","year":"2018","journal-title":"Transplantation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/infdis\/jiaa727","article-title":"CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients","volume":"224","author":"Donadeu","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial","volume":"74","author":"Facundo","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.healun.2022.05.004","article-title":"Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients","volume":"41","author":"Gardiner","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.transproceed.2019.11.002","article-title":"Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients with a High Risk of CMV Disease (D+\/R\u2212): A Case Series","volume":"52","author":"Gentil","year":"2020","journal-title":"Transplant. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","article-title":"Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation","volume":"5","author":"Meesing","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.transproceed.2017.07.001","article-title":"Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience","volume":"49","author":"Favi","year":"2017","journal-title":"Transplant. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/tri.12378","article-title":"Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy","volume":"27","author":"Gentil","year":"2014","journal-title":"Transpl. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e01040-17","DOI":"10.1128\/JCM.01040-17","article-title":"Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection","volume":"56","author":"Chiereghin","year":"2018","journal-title":"J. Clin. Microbiol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:33:02Z","timestamp":1760113982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["v16111781"],"URL":"https:\/\/doi.org\/10.3390\/v16111781","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}